Abstract
One hundred and ninety-one adults with acute myelogenous leukaemia were treated with combination chemotherapy consisting of daunorubicin and cytosine arabinoside (Barts III). Sixty-three patients achieved remission and were admitted to one of 3 trials of active immunotherapy: immunotherapy alone, immunotherapy and maintenance chemotherapy or neither of these. All patients had weekly clinical and blood examination and monthly marrow examination. Reinduction chemotherapy was given as soon as relapse was diagnosed in the marrow. The most striking observation was that immunotherapy was associated with easy and repeated reinduction of remission and marked prolongation of survival after first relapse when compared with immunotherapy plus chemotherapy. The possible reasons for this and the value of immunotherapy are discussed in relation to the third trial still in progress which includes 2 maintenance arms, immunotherapy alone and surveillance only.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Harris, R., Zuhrie, S., Freeman, C. et al. Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions. Br J Cancer 37, 282–288 (1978). https://doi.org/10.1038/bjc.1978.37
Issue Date:
DOI: https://doi.org/10.1038/bjc.1978.37
This article is cited by
-
Immunotherapy in the treatment of acute myelogenous leukemia (AML): Rationale, results and future prospects
Klinische Wochenschrift (1983)